Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.

NCT00502164 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00502164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00502164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose Escalation Study to Assess the Safety and Tolerability of AZD2171 Following Multiple Oral Doses in Subjects With Advanced Prostate Cancer.
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2004
Completion date
Not reported
Enrollment
40 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate adenocarcinoma